濕性老年黃斑部病變市場：KOL 洞察

隨著羅氏 Vabysmo（Bayer/Regeneron Eylea 的競爭對手）的推出，一線藥物的模式正在改變。 另一方面，標籤外阿瓦斯汀仍然是一種具有成本效益的選擇，但新的進展可能會減少其使用。 展望未來，重點是延長治療間隔、改善視力和侵入性較小的選擇，突顯基因療法、酪胺酸激□抑制劑和 D 4517.2 和 Axpaxli 等創新藥物的潛力。 在 wAMD 治療的這個關鍵時刻，需要採取策略重點來解決未滿足的需求並採用新的治療途徑。

本報告考察了全球濕性老年黃斑部病變市場，並提供了市場概述，包括已上市的治療方法、管道趨勢和未來前景。

目錄

執行摘要

處理演算法

研究目的

VEGF抑制劑

• 市售治療方法

VEGF抑制劑

• 標籤外使用市售治療方法
• 管道療法

酪胺酸激□抑制劑

• 管道療法

基因治療

• 管道療法

未來的治療範例

• 主要見解摘要
  • 開發治療 wAMD 藥物的製藥公司應專注於治療持續時間、給藥便利性、安全性和新的治療途徑。

附錄

With the introduction of Roche's Vabysmo challenging Bayer/Regeneron's Eylea, the dynamics of first-line choices are shifting. Meanwhile, off-label Avastin remains a cost-effective option, though its usage may wane with new advancements. As we look to the future, the focus sharpens on longer treatment intervals, improved visual acuity, and less invasive options, highlighting the potential of gene therapies, tyrosine kinase inhibitors, and innovative drugs like D 4517.2 and Axpaxli. This pivotal moment in wAMD treatment calls for a strategic pivot towards addressing unmet needs and embracing novel therapeutic pathways.

Table of Contents

Executive summary (14)

Treatment algorithm

Research objectives (2)

VEGF inhibitors (71)

• Marketed therapies (71)
  • Vabysmo (faricimab; Roche) (21)
  • Eylea (aflibercept; Bayer/Regeneron Pharmaceuticals) (21)
  • Lucentis (ranibizumab; Roche/Novartis) (18)
  • Beovu (brolucizumab; Novartis) (11)

VEGF inhibitors (70)

• Marketed therapies used off label (13)
  • Avastin (bevacizumab; Roche) (13)
• Pipeline therapies (57)
  • Sozinibercept (OPT-302; Opthea) (16)
  • D-4517.2 (Asvattha Therapeutics) (17)
  • Lytenava (bevacizumab ophthalmic; Outlook Therapeutics) (14)
  • Yesafili (aflibercept biosimilar; Momenta Pharmaceuticals/Viatris/Biocon) (10)

Tyrosine kinase inhibitors (24)

• Pipeline therapies (24)
  • Axpaxli (axitinib intravitreal implant/OTX-TKI; Ocular Therapeutix) (12)
  • Vorolanib (Equinox Sciences/EyePoint Pharmaceuticals) (12)

Gene therapy (32)

• Pipeline therapies (32)
  • ABBV-RGX-314 (REGENXBIO/AbbVie) (22)
  • Ixoberogene soroparvovec (Ixo-vec; Adverum Biotechnologies) (10)

Future treatment paradigm (15)

• Key insights summary (15)
  • Pharma companies developing wAMD therapies should focus on treatment duration, ease of administration, safety and new therapeutic pathways (3)

Appendix (3)

• KOL details (3)
  • KOLs from the USA (1)
  • KOLs from Europe (1)